Wall Street brokerages expect TCR2 Therapeutics Inc. (NASDAQ:TCRR) to announce earnings of ($0.65) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for TCR2 Therapeutics’ earnings. The highest EPS estimate is ($0.46) and the lowest is ($0.77). TCR2 Therapeutics posted earnings per share of ($0.56) during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.1%. The firm is expected to issue its next earnings report on Thursday, November 11th.
On average, analysts expect that TCR2 Therapeutics will report full year earnings of ($2.61) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($2.12). For the next financial year, analysts anticipate that the firm will report earnings of ($2.89) per share, with EPS estimates ranging from ($3.35) to ($2.60). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow TCR2 Therapeutics.
TCR2 Therapeutics (NASDAQ:TCRR) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.04).
Shares of TCRR traded down $5.73 on Friday, reaching $9.99. 6,915,518 shares of the company’s stock were exchanged, compared to its average volume of 411,131. The stock has a market capitalization of $381.62 million, a P/E ratio of -4.29 and a beta of 2.10. TCR2 Therapeutics has a 12 month low of $9.94 and a 12 month high of $35.86. The business has a 50 day moving average price of $14.95 and a two-hundred day moving average price of $18.75.
Several hedge funds and other institutional investors have recently bought and sold shares of TCRR. Point72 Hong Kong Ltd acquired a new position in shares of TCR2 Therapeutics during the first quarter valued at approximately $42,000. FORA Capital LLC increased its stake in shares of TCR2 Therapeutics by 255.8% during the second quarter. FORA Capital LLC now owns 2,608 shares of the company’s stock valued at $43,000 after acquiring an additional 1,875 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in TCR2 Therapeutics during the first quarter worth approximately $95,000. E Fund Management Co. Ltd. bought a new stake in TCR2 Therapeutics during the first quarter worth approximately $106,000. Finally, Metropolitan Life Insurance Co NY boosted its holdings in TCR2 Therapeutics by 114,312.5% during the second quarter. Metropolitan Life Insurance Co NY now owns 9,153 shares of the company’s stock worth $150,000 after buying an additional 9,145 shares in the last quarter. Institutional investors and hedge funds own 91.77% of the company’s stock.
TCR2 Therapeutics Company Profile
TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.
Recommended Story: Dual Listing What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.